# What is GHK-Cu?

Updated October 17, 2026. Source: https://whatisghkcu.com/

## Short answer

GHK-Cu is a small peptide made of three amino acids, glycine, histidine and lysine, bound to copper, and it occurs naturally in human blood, saliva and urine.[1][2] It is a widely used skincare ingredient whose cosmetic ingredient name is **copper tripeptide-1**.[2][4] Injectable GHK-Cu is not an FDA-approved drug, and FDA’s current compounding category for it excludes injectable use.[6][10]

## Quick fit check

If any of these apply, mention them in the assessment:

- **You have had a skin reaction to copper before:** Copper allergy is uncommon, but in a few cases copper causes real allergic reactions.[25] A provider reviewing your assessment will weigh any past reaction.
- **You compete in a sport with drug testing:** The blend offered here also contains BPC-157 and TB-500, which are prohibited under the 2027 World Anti-Doping Agency list.[24]
- **You only want a cream or serum for your skin:** Copper peptide serums and creams are cosmetics that need no FDA approval before sale, while GHK-Cu blends with other peptides are taken as injections.[6][8]
- **You want a treatment FDA has approved:** GHK-Cu is not an FDA-approved drug, and BPC-157 is not approved for human use by FDA or any other health authority.[6][23] A provider can tell you whether an approved option fits your goal.
- **You have used peptides bought online as research chemicals:** Grey-market peptides are often labeled for research use only and come with no assurance of quality or dose.[6][7] Tell the provider what you used.

## Key facts

- **What it is:** A three amino acid peptide (glycyl-L-histidyl-L-lysine, or GHK) that binds copper to form GHK-Cu.[1]
- **Found naturally:** In human plasma, saliva and urine. Plasma levels fall from about 200 ng/mL at age 20 to about 80 ng/mL by age 60.[1]
- **Main forms:** Topical serums and creams, injections, and injectable blends with other peptides.[6]
- **Studied for:** Mainly skin aging, plus wound healing and hair growth. Most human trials are small and use topical products.[6][19]
- **FDA status:** Not an FDA-approved drug.[6] FDA lists GHK-Cu as under evaluation for pharmacy compounding, except for injectable routes.[10]
- **On ingredient labels:** Copper tripeptide-1. Other names include prezatide copper and GHK copper.[4]

## Regulatory timeline

| Date | What happened |
| --- | --- |
| 1973 | GHK-Cu is first isolated from human albumin.[1] |
| September 29, 2023 | FDA places GHK-Cu for injectable routes in category 2, its list of compounding substances that may pose significant safety risks.[13] |
| April 22, 2026 | FDA removes non-injectable GHK-Cu from category 1 after its nominations are withdrawn.[10] FDA’s category 2 page, updated that day, lists injectable GHK-Cu among withdrawn nominations.[12] |
| May 14, 2026 | FDA says non-injectable GHK-Cu will be added back to category 1 and that it plans to consult its advisory committee on GHK-Cu before the end of February 2027.[10] |
| July 23 to 24, 2026 | FDA’s compounding advisory committee reviews seven other peptides, including BPC-157 and TB-500. GHK-Cu is not on the agenda.[15] |
| October 14, 2026 | White House reviewers receive an FDA interim access policy for compounding certain peptides. Its covered substances are not public.[17] |

## What it is

- **Three amino acids plus copper:** GHK is short for glycyl-L-histidyl-L-lysine, a chain of three amino acids: glycine, histidine and lysine.[1] It has a strong affinity for copper and readily forms the complex GHK-Cu.[1] At neutral pH, one copper ion binds one GHK peptide.[3]
- **Where it occurs in the body:** GHK is found naturally in human plasma, saliva and urine, and its level declines with age.[1] The GHK sequence is also part of type I collagen, and it can be released at the site of an injury when that collagen breaks down.[2]
- **How it was discovered:** Loren Pickart isolated GHK-Cu in 1973 as an activity in human albumin that made old human liver tissue produce proteins like younger tissue.[1] Later work identified that activity as the three amino acid peptide GHK.[1]
- **Other names:** Chemical databases list GHK-Cu as copper tripeptide-1 (its cosmetic ingredient name), prezatide copper, GHK copper and CG-copper peptide.[4][5]

## Forms you’ll see

- **Topical serums and creams:** Copper peptide serums and creams have been on the market for decades.[6] GHK-Cu is widely used in skin and hair products.[2]
- **Injections:** A newer trend is injecting GHK-Cu under the skin instead of applying it.[6] Many people buy injectable versions from a grey market of online sellers.[6] NPR reported on a clinic that offers GHK-Cu injections made by a licensed compounding pharmacy, despite current restrictions.[6]
- **Blends with other peptides:** Injectable GHK-Cu is sometimes stacked with other peptides promoted for tissue repair and anti-aging.[6] Lab testing reported in 2026 found some vials labeled as one peptide blend that actually contained another.[7]
- **BPC-157:** A peptide that FDA describes as 15 amino acids long.[21] It contains part of a “body protection compound” first isolated from human stomach juice, and the BPC-157 sold today is all made synthetically.[23]
- **TB-500:** A short peptide of seven amino acids that FDA lists as a fragment of thymosin beta-4.[12][22]

## Legal and regulatory status

- **Not an approved drug:** GHK-Cu is not an FDA-approved drug.[6] DrugBank lists it as investigational.[5]
- **In skincare:** Cosmetic products and ingredients, other than color additives, do not need FDA approval before they are sold, and the companies that make them are legally responsible for their safety.[8] A product sold as a cosmetic can legally be a drug if its claims say it will affect the body’s structure or function, such as regenerating cells.[9]
- **Compounding, non-injectable:** Under section 503A, pharmacies may compound only with bulk substances that have a USP or NF monograph, are part of an FDA-approved drug, or are on FDA’s 503A bulks list.[11] FDA lists GHK-Cu, except for injectable routes, in category 1, substances still under evaluation.[10] For category 1, FDA does not intend to take action against compounders who meet the conditions in its guidance.[11]
- **Compounding, injectable:** In September 2023, FDA placed injectable GHK-Cu in category 2, citing a possible risk of immune reactions from clumping and peptide-related impurities.[13] As of April 2026, FDA lists it among category 2 substances whose nominations were withdrawn.[12] The category 1 listing does not cover injectable routes.[10]
- **Advisory review ahead:** FDA has said it plans to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether GHK-Cu should be added to the 503A bulks list.[10] FDA’s meeting page lists GHK-Cu with four other substances for that review, including LL-37 and melanotan II.[14] As of October 16, 2026, no date had been set.[18]
- **Pending interim policy:** On October 14, 2026, White House reviewers received an FDA “Interim Access Policy for Compounding Using Certain Peptides,” listed as pending review.[17] The public record does not disclose which substances it covers.[17] Any policy issued will also need to be read alongside state pharmacy law.[17]
- **BPC-157 and TB-500:** BPC-157 is not approved for human clinical use by FDA or any other global health authority.[23] In July 2026, FDA advisers voted to recommend adding BPC-157 and TB-500 to the 503A bulks list, although FDA staff opposed it.[16] The vote is non-binding, and FDA must still publish proposed rules before anything becomes official.[16]

## What it’s studied for

- **Skin aging:** A 2026 systematic review found 20 studies, 18 preclinical and 2 randomized trials.[19] In the trials, GHK-Cu reduced wrinkle volume and depth compared with controls, but the review noted few well-designed clinical trials.[19]
- **Wound healing and hair:** Controlled human studies have focused mostly on skin, and to a lesser extent on wound healing and hair growth.[6] A phase 2 study in acute wounds was still recruiting in August 2026, with no results.[3]
- **Injected use:** No published human studies show that injecting GHK-Cu is safe and effective.[6] A 2026 review found no clinical data supporting GHK-Cu for muscle, bone or joint conditions.[20]

## Risks and unknowns

- **Injected forms:** FDA says compounded injectable GHK-Cu may pose a risk of immune reactions due to clumping and peptide-related impurities, and that limited human data exist to judge its safety.[12]
- **Too much copper:** Potential risks of injecting include overloading the body with copper and triggering a dangerous immune reaction.[6] One clinician told NPR he has seen self-injectors with raised liver enzymes and copper levels, though it was unclear whether the peptide or impurities were to blame.[6]
- **Product quality:** Consumers largely buy injectable GHK-Cu from unregulated suppliers, with no assurance of quality or dose.[6] Grey-market peptides are often labeled “for research purposes only,” which lets sellers sidestep regulatory oversight.[7]
- **Combining peptides:** Experts say it is not clear how peptides taken together interact with one another.[7] FDA says it lacks enough information to know whether BPC-157 or TB-500 would cause harm in humans.[12]
- **Skin reactions:** Copper is a very weak skin allergen compared with other metals, but in a few cases it causes real allergic reactions.[25]
- **Athletes:** BPC-157 and TB-500 are prohibited under the 2027 World Anti-Doping Agency list, which takes effect January 1, 2027.[24]

## Common questions

### Is GHK-Cu natural?

Yes. GHK occurs naturally in human plasma, saliva and urine, and levels drop with age.[1] Natural does not mean risk-free: peptides can be potent and even toxic, and grey-market GHK-Cu comes with no assurance of quality or dose.[6][7]

### Is GHK-Cu the same as copper peptides?

Not exactly. News coverage often uses “copper peptides” to mean GHK-Cu.[6] Researchers, however, separate GHK-Cu from other GHK-derived copper peptides and from copper peptides not based on GHK.[3] On skincare labels, GHK-Cu appears as copper tripeptide-1.[4]

### Is GHK-Cu FDA-approved?

No. GHK-Cu is not an approved drug.[6] Cosmetic ingredients do not need FDA approval before sale.[8] For compounding, FDA lists GHK-Cu as under evaluation except for injectable routes, and it plans an advisory committee review before the end of February 2027.[10]

### What’s the difference between topical and injectable GHK-Cu?

Topical GHK-Cu is applied to the skin, has been sold for decades, and is the form used in most human trials.[6] Injected GHK-Cu has no published human studies showing it is safe and effective.[6] FDA has flagged possible immune reactions with injectable forms, and its compounding category 1 listing excludes injectable routes.[10][12]

### What else is in a GHK-Cu blend?

It depends on the product. Injectable GHK-Cu is sometimes mixed with peptides promoted for tissue repair and anti-aging.[6] Disclosure: the blend offered through the assessment on this page also contains BPC-157 and TB-500. FDA reviewers cited a lack of human safety information on both.[21][22]

### Is GHK-Cu safe?

For injections, safety is not established: there are no published human studies showing injecting it is safe and effective, and FDA has flagged possible immune reactions.[6][12] Copper peptide creams have been sold for decades, and copper rarely causes skin allergy.[6][25] Talk to a clinician before using any form.

## Next step

**See if a provider recommends GHK-Cu.** Complete an online health assessment. A licensed provider reviews it and decides whether a GHK-Cu blend or another option is appropriate. The blend offered through this assessment also contains BPC-157 and TB-500.

What the assessment includes:

- Online health assessment
- Review by a licensed provider
- Shipped to you if prescribed
- Card held at checkout, charged only if prescribed

How to get started:

1. **Answer health questions.** An online assessment about your health, history and goals.
2. **A licensed provider reviews it.** They decide whether a prescription is safe and appropriate for you.
3. **If prescribed, it ships to you.** Your card is only held at checkout. You’re charged only if a provider prescribes.

Not everyone qualifies. A provider decides based on your health history.

Start the assessment: https://whatisghkcu.com/go/md/agent

Assessments are completed with a partner telehealth provider. This site may earn a commission if you start one through it.

## Sources

1. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (Pickart L, Vasquez-Soltero JM, Margolina A). BioMed Research International, via PubMed Central. July 7, 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
2. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (Pickart L, Margolina A). International Journal of Molecular Sciences, via PubMed Central. July 7, 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
3. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap (Mateescu DM, et al.). Pharmaceutics, via PubMed Central. August 27, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13610439/
4. Prezatide copper (Copper tripeptide-1), CID 71587328. PubChem, National Library of Medicine. Accessed October 17, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/71587328
5. Prezatide copper (DB14683). DrugBank. Accessed October 17, 2026. https://go.drugbank.com/drugs/DB14683
6. The copper peptide trend has gone from creams to injections, ahead of the science (Will Stone). NPR. September 7, 2026. https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe
7. What to Know About the ‘Anti-Aging’ Peptide Shots Flooding Social Media (Dominique Mosbergen). TIME. February 24, 2026. https://time.com/7380810/anti-aging-peptide-shots-social-media/
8. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated. U.S. Food and Drug Administration. Updated November 18, 2025. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated
9. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). U.S. Food and Drug Administration. Updated September 11, 2024. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
10. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1 to 3). U.S. Food and Drug Administration. Updated May 14, 2026. https://www.fda.gov/media/94155/download
11. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. U.S. Food and Drug Administration. Content current as of May 14, 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
12. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. Content current as of April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
13. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (archived version). U.S. Food and Drug Administration, via Internet Archive. Content current as of July 8, 2025. https://web.archive.org/web/20260106183043/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
14. Meeting of the Pharmacy Compounding Advisory Committee (upcoming). U.S. Food and Drug Administration. Content current as of April 15, 2026. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
15. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. Content current as of August 6, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
16. FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?. ABC News. July 24, 2026. https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915
17. FDA Submits Interim Peptide Compounding Policy for White House Review: What Pharmacies Should Know. Buchanan Ingersoll & Rooney PC. October 16, 2026. https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know
18. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight LLP. October 16, 2026. https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know
19. The Regenerative Potential of GHK-Cu in Aesthetic Medicine (Mokhtar J, et al.). Aesthetic Surgery Journal, via PubMed. August 20, 2026. https://pubmed.ncbi.nlm.nih.gov/42619529/
20. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (Mayfield CK, et al.). American Journal of Sports Medicine, via PubMed. January 2026. https://pubmed.ncbi.nlm.nih.gov/41476424/
21. FDA Briefing Document: BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. July 2026. https://www.fda.gov/media/193343/download
22. FDA Briefing Document: TB-500-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. July 2026. https://www.fda.gov/media/193349/download
23. BPC-157: What Athletes Should Know About the Prohibited Experimental Peptide. U.S. Anti-Doping Agency (USADA). Updated August 10, 2026. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
24. Athlete Advisory: What's New on the 2027 WADA Prohibited List?. U.S. Anti-Doping Agency (USADA). October 6, 2026. https://www.usada.org/spirit-of-sport/athlete-advisory-2027-prohibited-list/
25. Copper hypersensitivity (Fage SW, Faurschou A, Thyssen JP). Contact Dermatitis, via PubMed. October 2014. https://pubmed.ncbi.nlm.nih.gov/25098945/

---

General education, not medical advice. Talk to a licensed clinician before starting or changing any medicine.